prostate tissue microarray (tma) Search Results


prostate cancer tissue microarrays (tma)  (BioChain Institute)
90
BioChain Institute prostate cancer tissue microarrays (tma)
Prostate Cancer Tissue Microarrays (Tma), supplied by BioChain Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostate cancer tissue microarrays (tma)/product/BioChain Institute
Average 90 stars, based on 1 article reviews
prostate cancer tissue microarrays (tma) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human prostate tissue microarray (tma)  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare human prostate tissue microarray (tma)
AXL is not expressed in human prostate tumors. A, AXL expression prostate cancer patients who did and did not experience a biochemical recurrence (n = 1405 patients, GenomeDx GRID dataset). P value was calculated using the Wilcoxon rank test. B, Recurrence-free survival of patients with high (above the median) and low (below the median) AXL expression (n = 571 patients, Taylor et al, 2010 visualized and analyzed with Project Betastasis). C, Representative images of AXL IHC staining of a prostate tissue <t>microarray;</t> LN, lymph node. C42B cells served as a negative control, DU145 as a positive control. All images at original magnification x 200. D, AXL IHC staining in metastatic patient tissue; upper panel scale bar, 100 μm; lower panel scale bar, 50 μm.
Human Prostate Tissue Microarray (Tma), supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human prostate tissue microarray (tma)/product/Johns Hopkins HealthCare
Average 90 stars, based on 1 article reviews
human prostate tissue microarray (tma) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
prostate cancer tissue microarray tma  (Servicebio Inc)
86
Servicebio Inc prostate cancer tissue microarray tma
CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue <t>microarray</t> <t>(TMA)-based</t> immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I
Prostate Cancer Tissue Microarray Tma, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prostate cancer tissue microarray tma/product/Servicebio Inc
Average 86 stars, based on 1 article reviews
prostate cancer tissue microarray tma - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


AXL is not expressed in human prostate tumors. A, AXL expression prostate cancer patients who did and did not experience a biochemical recurrence (n = 1405 patients, GenomeDx GRID dataset). P value was calculated using the Wilcoxon rank test. B, Recurrence-free survival of patients with high (above the median) and low (below the median) AXL expression (n = 571 patients, Taylor et al, 2010 visualized and analyzed with Project Betastasis). C, Representative images of AXL IHC staining of a prostate tissue microarray; LN, lymph node. C42B cells served as a negative control, DU145 as a positive control. All images at original magnification x 200. D, AXL IHC staining in metastatic patient tissue; upper panel scale bar, 100 μm; lower panel scale bar, 50 μm.

Journal: Molecular cancer research : MCR

Article Title: AXL is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer

doi: 10.1158/1541-7786.MCR-18-0718

Figure Lengend Snippet: AXL is not expressed in human prostate tumors. A, AXL expression prostate cancer patients who did and did not experience a biochemical recurrence (n = 1405 patients, GenomeDx GRID dataset). P value was calculated using the Wilcoxon rank test. B, Recurrence-free survival of patients with high (above the median) and low (below the median) AXL expression (n = 571 patients, Taylor et al, 2010 visualized and analyzed with Project Betastasis). C, Representative images of AXL IHC staining of a prostate tissue microarray; LN, lymph node. C42B cells served as a negative control, DU145 as a positive control. All images at original magnification x 200. D, AXL IHC staining in metastatic patient tissue; upper panel scale bar, 100 μm; lower panel scale bar, 50 μm.

Article Snippet: Human prostate tissue microarray (TMA) staining This study was approved by the Johns Hopkins institutional internal review board and followed the U.S. Common Rule.

Techniques: Expressing, Immunohistochemistry, Microarray, Negative Control, Positive Control

CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue microarray (TMA)-based immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I

Journal: Journal of Translational Medicine

Article Title: Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis

doi: 10.1186/s12967-025-07529-5

Figure Lengend Snippet: CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue microarray (TMA)-based immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I

Article Snippet: The prostate cancer tissue microarray (TMA) was obtained from Servicebio Technology (#PC-1601).

Techniques: Expressing, Comparison, Immunohistochemical staining, Staining, Marker, Microarray, Immunohistochemistry